Opinion|Videos|March 20, 2025

Clinical Perspectives on Early Use of RAD-ENZ

Author(s)Evan Yu, MD , Jack R. Andrews, MD, Jacob J. Orme, MD, PhD

Panelists discuss how early implementation of RAD-ENZ combination therapy requires careful consideration of patient characteristics, disease burden, and long-term treatment planning while potentially offering the greatest benefit when initiated before significant disease progression occurs.

Episodes in this series

EP. 1 The Contemporary Treatment Landscape of mCRPC

EP. 1 The Contemporary Treatment Landscape of mCRPC

EP. 2 Treatment Selection and the Use of Combination Therapies in mCRPC

EP. 2 Treatment Selection and the Use of Combination Therapies in mCRPC

EP. 3 The PEACE-3 Trial

EP. 3 The PEACE-3 Trial

EP. 4 The Safety Profile of RAD-ENZ

EP. 5 Applying Results From PEACE-3 to Your Patient Population

EP. 5 Applying Results From PEACE-3 to Your Patient Population

EP. 6 The Future of RAD-ENZ Combination Therapy

EP. 6 The Future of RAD-ENZ Combination Therapy

EP. 7 Treatment Selection for mCRPC

EP. 7 Treatment Selection for mCRPC

EP. 8 Clinical Perspectives on Early Use of RAD-ENZ

EP. 8 Clinical Perspectives on Early Use of RAD-ENZ

EP. 9 The DORA Trial

EP. 9 The DORA Trial

EP. 10 Addressing Remaining Unmet Needs in mCRPC

EP. 10 Addressing Remaining Unmet Needs in mCRPC

Video content above is prompted by the following:

What are your clinical perspectives on using this combination therapy upfront and early in the disease stage?
How can the findings from PEACE-3 influence the design of future trials, particularly with respect to patient selection, end points, and safety monitoring?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Precision Medicine and Patient Selection in mHSPC

ByScott Sellinger, MD, FACS

August 20th 2026

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

ByNeal D. Shore, MD, FACS,Chandler Park, MD

August 19th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Initial prostate cancer presentation, family history linked to survival in mCRPC

State of Men’s Health Act: What urologists need to know

FDA greenlights phase 1 trial of ADI-212 in mCRPC

Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment

UF urology chiefs reflect on lessons and milestones from residency